RxDoctor Payments Data

Anjali Advani, MD

Hematology · Cleveland, OHNPI 1942262738

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Pfizer at 51.1% of the total. Reporting peaked in 2019 at $30,096 and has fallen 67.6% since, to $9,738 in 2025.

$79,068in general payments, 2019–2025

Across 57 payments — averaging $1387.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$40K
  • Gilead$11K
  • AstraZeneca$6K
  • Amgen$5K
  • Jazz Pharmaceuticals Inc.$4K
  • Syndax Pharmaceuticals, Inc.$4K
  • plus $9K from 5 others
$6,815,964in research payments, 2019–2025

Across 247 payments — averaging $27,595 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$5.4M
  • Pfizer$290K
  • Servier Bioinnovation$265K
  • AbbVie$264K
  • Amgen$249K
  • Seagen Inc.$173K
  • plus $146K from 4 others

What the payments were for

  • Consulting fees$38,38949%
  • Speaking & faculty fees$39,59050%
  • Travel & lodging$1730%
  • Food & beverage$9111%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer33$40,404
Gilead4$11,040
AstraZeneca5$6,122
Amgen3$4,895
Jazz Pharmaceuticals Inc.2$3,845
Syndax Pharmaceuticals, Inc.2$3,616
Takeda Pharmaceuticals U.S.A., Inc.1$3,299
Novartis1$2,800
Whitehall International Inc1$1,500
Seagen Inc.4$1,480
Astellas Pharma US Inc1$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$79,068 in reported general payments places this provider in the 85th percentile of 84 hematology providers in Ohio.

See all hematology providers in Ohio

Medicare billing

Part B allowed, 2024
$33,551
Medicare patients
92
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TibsovoIvosidenib21$635,810
ScemblixAsciminib Hydrochloride19$588,420
ImbruvicaIbrutinib24$393,659
PromactaEltrombopag Olamine13$349,537
SprycelDasatinib20$284,706
JakafiRuxolitinib Phosphate18$201,646
Imatinib Mesylate74$165,614
BosulifBosutinib11$153,273
GleevecImatinib Mesylate13$150,458
Acyclovir101$1,943
Gabapentin36$507
Mirtazapine29$470
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$449
Ondansetron Hcl26$407
Allopurinol18$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisScemblix, Promacta, Gleevec$2,800$1,088,41545 claims
PfizerBosulif$40,404$153,27311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 84 hematology providers in Ohio.

Other hematology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →